Generic Name:
vedolizumab
Project Status:
Complete
Therapeutic Area:
Ulcerative Colitis
Manufacturer:
Takeda Canada Inc.
Call for patient/clinician input open:
Brand Name:
Entyvio
Project Line:
Reimbursement Review
Project Number:
SR0635-000
Call for patient/clinician input closed:
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, a TNF antagonist.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Ulcerative Colitis
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.